Back to top

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on ACADIA Pharmaceuticals, with a price target of $25.00. Ma...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ACADIA Pharmaceuticals Inc. (ACAD)